A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped To enable development of an enhanced version of the vaccine

Conditions

Herpes Simplex

Interventions

BIOLOGICAL: Lower dose formulation of HSV vaccine (GSK4108771A)
BIOLOGICAL: Low dose formulation of HSV vaccine (GSK4108771A)
BIOLOGICAL: Medium dose formulation of HSV vaccine (GSK4108771A)
BIOLOGICAL: High dose formulation of HSV vaccine (GSK4108771A)
DRUG: Placebo (saline)

Sponsor

GlaxoSmithKline